Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAK-ER
2024-517414-15-00Phase 2Authorised
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised trial of palbociclib and fulvestrant in breast cancer (3 arms), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoints: ctDNA detection during surveillance phase and Relapse-free survival. Planned start Oct 2024; status: authorised.
02
Drugs
palbociclibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-517414-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517414-15-00.